William Blair Brokers Increase Earnings Estimates for ARCT

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Research analysts at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a report released on Tuesday, August 12th. William Blair analyst M. Minter now expects that the biotechnology company will post earnings of ($0.58) per share for the quarter, up from their prior estimate of ($0.81). The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.22) per share. William Blair also issued estimates for Arcturus Therapeutics’ Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($2.15) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.44) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.68) EPS and FY2027 earnings at $1.83 EPS.

A number of other analysts also recently commented on the company. Scotiabank reiterated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Wednesday, July 2nd. Wall Street Zen raised Arcturus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. Wells Fargo & Company cut their price target on Arcturus Therapeutics from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday. Canaccord Genuity Group cut their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Finally, Citigroup reissued a “buy” rating and issued a $49.00 price target (up from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $50.00.

Arcturus Therapeutics Stock Performance

ARCT opened at $19.23 on Thursday. The business’s fifty day moving average is $13.44 and its two-hundred day moving average is $13.31. The company has a market cap of $522.29 million, a price-to-earnings ratio of -8.62 and a beta of 2.26. Arcturus Therapeutics has a one year low of $8.04 and a one year high of $25.88.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.77. The company had revenue of $28.30 million for the quarter, compared to the consensus estimate of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.

Hedge Funds Weigh In On Arcturus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Arcturus Therapeutics by 101.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,332 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 16,306 shares during the last quarter. Diversify Advisory Services LLC increased its stake in Arcturus Therapeutics by 1,136.1% in the second quarter. Diversify Advisory Services LLC now owns 222,500 shares of the biotechnology company’s stock valued at $2,895,000 after purchasing an additional 204,500 shares during the last quarter. Diametric Capital LP increased its stake in Arcturus Therapeutics by 368.8% in the second quarter. Diametric Capital LP now owns 59,195 shares of the biotechnology company’s stock valued at $770,000 after purchasing an additional 46,569 shares during the last quarter. Kennedy Capital Management LLC increased its stake in Arcturus Therapeutics by 4.9% in the second quarter. Kennedy Capital Management LLC now owns 11,674 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 544 shares during the last quarter. Finally, Invesco Ltd. increased its stake in Arcturus Therapeutics by 28.6% in the second quarter. Invesco Ltd. now owns 44,861 shares of the biotechnology company’s stock valued at $584,000 after purchasing an additional 9,965 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.